Genomics Flashcards
amitryptyline metabolism pathway
2C19 activates it
2D6 deactivates
2D6 genotypes
- normal = 1, 2
- non-functional = 3-8
amitryptyline 2C19 recommendations
- avoid in ultrarapid and poor metabolizers
- standard dose in extensive and intermediate
amitryptyline 2D6 recommendations
- avoid in ultrarapid and poor
- 25% reduction in intermediate
simvastatin gene involved in metabolism
SLCO1B1
simvastatin genotypes/phenotypes
- TT = standard
- TC = intermediate
- CC = low function
simvastatin dosing recommendations
- TT = normal
- TC = lower dose or alternative
- CC = lower dose or alternative
methotrexate metabolism by
SLC19A1
methotrexate mutation
SNP at SLC19A1
methotrexate recommendations
no definitive recommendations
-higher risk of toxicity has been seen
clopidogrel metabolism
2C19
clopidogrel phenotypes
- Ultra = 17
- extensive = 1/1
- intermediate = 1 and 2-8 or 17 and 2-8
- poor = 2-8
clopidogrel recommendations
any loss of function allele should get alternative therapy
-still use in ultra rapid
bupropion metabolised by
2B6
bupropion moderately inhibits
2D6
gene related to smoking cessation in bupropion
ANKK1
bupropion recommendations
- loss of 2B6 may need other treatment
- ANKK1 AA or AG may have decreased response
codeine metabolism
2D6
codeine recommendations
-alternative in ultra rapid and poor
aripiprazole metabolism
3A4
2D6
aripiprazole recommendations
- poor 2D6 = reduce dose by half
- poor 2D6 + 3A4 inhib = reduce to 1/4
drugs to do HLA-B*5701 test for
abacavir
carbamazepine
patients to do HLA testing when using allopurinol
chinese
warfarin metabolism
VKORC
2C9
normal VKORC1 genotypes
G
C
VKORC1 mutations
G > A
C > T
2C9 genotypes
1 - normal
2,3 - reduced
warfarin recommendations
no specific, maybe use table
irinotecan mutation
UGT1A1*28
irinotecan recommendations
if UGT1A1*28 is present reduce dose by 30%
tamoxifen metabolism
mainly activated 2D6
some 2C9 and 3A4
tamoxifen recommendations
- avoid in poor
- consider something else in intermediate
- ultra rapid is fine
gene of interest in cetuximab and panitumumab
KRAS
if its not present then they won’t work